Literature DB >> 24295792

Visceral disease in castration-resistant prostate cancer.

C Pezaro1, A Omlin1, D Lorente1, D Nava Rodrigues1, R Ferraldeschi1, D Bianchini1, D Mukherji1, R Riisnaes1, A Altavilla1, M Crespo1, N Tunariu1, J de Bono1, G Attard1.   

Abstract

Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%. Of the 92 patients with computed tomography performed within 3 mo of death, 49% had visceral metastases. Visceral metastases most commonly involved the liver (20%) and lung (13%). Median survival from diagnosis of visceral disease was 7.1 mo (95% confidence interval, 5.9-8.3). Survival was affected by the degree of bone involvement at detection of visceral disease, varying from 6.1 mo in men with more than six bone metastases to 18.2 mo in men with no bone metastases (p=0.001). Heterogeneity was noted in clinical phenotypes and prostate-specific antigen trends at development of visceral metastases. Visceral metastases are now more commonly detected in men with CRPC, likely due to the introduction of novel survival-prolonging treatments.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24295792      PMCID: PMC4881819          DOI: 10.1016/j.eururo.2013.10.055

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

Review 1.  Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Authors:  Carmel Pezaro; Gerhardt Attard
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

2.  Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.

Authors:  Laurence Collette
Journal:  Eur Urol       Date:  2007-08-28       Impact factor: 20.096

3.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

4.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

5.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Authors:  Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

6.  Liver metastases in prostate carcinoma: clinical characteristics and outcome.

Authors:  Damien Pouessel; Blandine Gallet; Frédéric Bibeau; Christophe Avancès; François Iborra; Pierre Sénesse; Stéphane Culine
Journal:  BJU Int       Date:  2006-11-28       Impact factor: 5.588

7.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Authors:  Juan Miguel Mosquera; Himisha Beltran; Kyung Park; Theresa Y MacDonald; Brian D Robinson; Scott T Tagawa; Sven Perner; Tarek A Bismar; Andreas Erbersdobler; Rajiv Dhir; Joel B Nelson; David M Nanus; Mark A Rubin
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

8.  BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams.

Authors:  Tim Hulsen; Jacob de Vlieg; Wynand Alkema
Journal:  BMC Genomics       Date:  2008-10-16       Impact factor: 3.969

9.  Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Authors:  Aurelius Omlin; Carmel Pezaro; Deborah Mukherji; Amy Mulick Cassidy; Shahneen Sandhu; Diletta Bianchini; David Olmos; Roberta Ferraldeschi; Gal Maier; Emilda Thompson; Chris Parker; Gerhardt Attard; Johann de Bono
Journal:  Eur Urol       Date:  2013-01-04       Impact factor: 20.096

10.  Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.

Authors:  O B Goodman; T W Flaig; A Molina; P F A Mulders; K Fizazi; H Suttmann; J Li; T Kheoh; J S de Bono; H I Scher
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-10-01       Impact factor: 5.554

  10 in total
  55 in total

1.  Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?

Authors:  Laura Evangelista; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01       Impact factor: 9.236

2.  Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Patrick M Cotogno; Lahiru K Ranasinghe; Elisa M Ledet; Brian E Lewis; Oliver Sartor
Journal:  Oncologist       Date:  2018-04-26

3.  The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.

Authors:  Francesco Ceci; Giulia Polverari; Jeremie Calais; Paolo Castellucci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12       Impact factor: 9.236

4.  Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.

Authors:  Jie-Fu Chen; Hao Ho; Jake Lichterman; Yi-Tsung Lu; Yang Zhang; Mitch A Garcia; Shang-Fu Chen; An-Jou Liang; Elisabeth Hodara; Haiyen E Zhau; Shuang Hou; Rafi S Ahmed; Daniel J Luthringer; Jiaoti Huang; Ker-Chau Li; Leland W K Chung; Zunfu Ke; Hsian-Rong Tseng; Edwin M Posadas
Journal:  Cancer       Date:  2015-05-14       Impact factor: 6.860

Review 5.  Translational and clinical implications of the genetic landscape of prostate cancer.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Felix Y Feng; Scott A Tomlins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

6.  PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.

Authors:  Francesco Ceci; Paolo Castellucci; Cristina Nanni; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11       Impact factor: 9.236

Review 7.  Multimodality Imaging of Prostate Cancer.

Authors:  Soleen Ghafoor; Irene A Burger; Alberto H Vargas
Journal:  J Nucl Med       Date:  2019-09-03       Impact factor: 10.057

8.  ECF chemotherapy for liver metastases due to castration-resistant prostate cancer.

Authors:  Shruti Gupta; Kylea Potvin; D Scott Ernst; Frances Whiston; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

9.  Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Authors:  Susan Halabi; William Kevin Kelly; Hua Ma; Haojin Zhou; Nicole C Solomon; Karim Fizazi; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Maha Hussain; Nicholas J Vogelzang; Ian M Thompson; Kim N Chi; Johann de Bono; Andrew J Armstrong; Mario A Eisenberger; Abderrahim Fandi; Shaoyi Li; John C Araujo; Christopher J Logothetis; David I Quinn; Michael J Morris; Celestia S Higano; Ian F Tannock; Eric J Small
Journal:  J Clin Oncol       Date:  2016-03-07       Impact factor: 44.544

10.  Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?

Authors:  Stéphane Oudard; Antoine Angelergues
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.